Sunday, August 24, 2025
spot_img

DCGI okays Glenmark’s FabiFlu tablet to treat COVID-19 patients

Date:

Share post:

spot_imgspot_img

GUWAHATI: Finally, a silver lining even as the dark cloud of COVID-19 pandemic continues to hover of the globe. India-based Glenmark Pharmaceuticals has launched antiviral drug Favipiravir, to be sold under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 symptoms.

FabiFlu is the first oral Favipiravir-approved medication for the treatment of Covid-19, the company said in a statement. The drug has received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) on Friday.

“This approval comes at a time when Covid-19 cases in India are spiralling like never before, putting tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha reportedly said.

The drug, called FabiFlu, will be marketed in some north Indian states soon. The drug will soon be available in hospitals and stores in a pack of 34 oral tables at moderately affordable price of Rs 103 per tablet.

 

spot_imgspot_img

Related articles

India suspends postal services to US due to customs confusion

New Delhi, Aug 23: Postal services to the US have been temporarily suspended, as US-bound air carriers have...

India-Australia wrap up 11th CECA talks

New Delhi, Aug 23: The 11th Round of India-Australia Comprehensive Economic Cooperation Agreement (Ind-Aus CECA) concluded on Saturday,...

India’s seafood exports hit $7.45 billion

Kochi, Aug 23: India’s seafood exports reached a remarkable 16,98,170 metric tonnes valued at Rs 62,408.45 crore ($7.45...

SEBI proposes increasing block deal minimum order size to Rs 25 crore

New Delhi, Aug 23: The Securities and Exchange Board of India (Sebi) has proposed raising the minimum order...